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Introduction: The Lungscape project was designed to address the 
impact of clinical, pathological, and molecular characteristics on out-
come in resected non–small- cell lung cancer (NSCLC).
Materials and Methods: A decentralized biobank with fully anno-
tated tissue samples was established. Selection criteria for participat-
ing centers included sufficient number of cases, tissue microarray 
building capability, and documented ethical approval. Patient selec-
tion was based on availability of comprehensive clinical data, radi-
cal resection between 2003 and 2009 with adequate follow-up, and 
adequate quantity and quality of formalin-fixed tissue.
Results: Fifteen centers contributed 2449 cases. The 5-year overall 
survival (OS) was 69.6% and 63.6% for stages IA and IB, 51.6% and 
47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA 
and IIIB, respectively (p < 0.001). Median and 5-year relapse-free 
survival (RFS) were 52.8 months and 47.3%, respectively. Distant 
relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% 
of patients. Based on multivariate analysis for the OS, RFS, and time 
to relapse, the factors significantly associated with all of them are 
performance status and pathological stage.
Conclusion: The aim of this report is to present the results from 
Lungscape, the first large series reporting on NSCLC surgical outcome 
measured not only by OS but also by RFS and time to relapse and 
including multivariate analysis by significant clinical and pathological 
prognostic parameters. As tissue from all patients is preserved locally 
and is available for detailed molecular investigations, Lungscape pro-
vides an excellent basis to evaluate the influence of molecular param-
eters on the disease outcome after radical resection, besides providing 
an overview of the molecular landscape of stage I to III NSCLC.
Key Words: NSCLC, TNM stage, Surgery, Patients’ and  pathological 
characteristics, Outcome.
(J Thorac Oncol. 2014;9: 1675–1684)
The seventh edition of the tumor, node, metastasis (TNM) system reliably serves in estimating the prognosis of 
patients with non–small-cell lung cancer (NSCLC) and pro-
vides the basis for decisions on treatment strategies. For oper-
able patients with earlier stages of disease, surgery remains 
the established standard of care. For patients with a complete 
resection of pathological stage II and III tumors, adjuvant che-
motherapy has been proven to increase the 5-year survival by 
an absolute 4.0%,1 whereas a benefit from adjuvant radiother-
apy remains uncertain and, if existing, probably is restricted to 
stage III disease.
The seventh edition of the TNM classification of 
NSCLC was published in 2009. It is built on the retrospective 
analysis of patients from 46 sources from more than 20 coun-
tries treated by all modalities from 1990 to 2000 to guarantee 
a 5-year follow-up. The survival analysis was based on 67,725 
cases of NSCLC, of which data on pathological stage were 
available in 16,952 cases.2
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Since the identification of activating mutations in the 
epidermal growth factor receptor gene as a molecular driver 
for a subset of NSCLC, it has become recognized that adeno-
carcinoma of the lung no longer represents a single entity but 
rather comprises a growing spectrum of distinct molecular 
subtypes for which specific systemic therapies have entered 
clinical practice or are currently under investigation.3 A simi-
lar, potentially even more complex picture is emerging in 
squamous cell lung cancer.4
The Lungscape project was designed to address the 
challenges of studying the molecular epidemiology of lung 
cancer and to expedite our knowledge of current and evolving 
clinical and molecular biomarkers. As the basis of this work, 
a decentralized biobank with fully annotated tissue samples 
was created to elucidate the outcome of clinically, pathologi-
cally, and molecularly characterized subgroups of resected 
stage I to III NSCLC. Fifteen centers contributed their data 
on a total of 2449 patients. The aim of this study is to describe 
the outcome, including overall survival (OS), as reported in 
the International Association for the Study of Lung Cancer 
database,2 but also for the first time in a large surgical series, 
relapse-free survival (RFS) and time to relapse (TTR), accord-
ing to pathological stage, histology, and clinical parameters 
for 2449 patients with resected NSCLC.
PATIENTS AND METHODS
Patient Selection and Data Capturing
Data on patients with pathological stage I to III NSCLC 
in 14 European and one Chinese center have been collected ret-
rospectively, according to the Lungscape protocol. Selection 
criteria for participating centers included sufficient numbers 
of cases, availability of a full clinicopathological data set, 
tissue microarray building capability, and documented ethi-
cal approval for investigations on tissue samples and sharing 
associated clinical data. Patient selection was based on radical 
surgical resection performed between January 1, 2003, and up 
to December 31, 2009, allowing for a follow-up of at least 3 
years, comprehensiveness of clinical annotation, and adequate 
formalin-fixed paraffin-embedded tissue.
After data capture in the iBiobank, a central electronic 
database used to store anonymized comprehensive molecular 
and clinical data, a systematic medical data review of every case 
was performed to check for plausibility, to optimize staging 
accuracy under the seventh TNM classification,2 and to confirm 
availability of tissue. To facilitate quality assurance in regard to 
tissue and pathological staging, upload of the original anony-
mized pathology reports to the iBiobank database was manda-
tory. Clinical data were categorized into mandatory parameters 
necessary for case submission and acceptance by central review, 
and desirable parameters as listed in Supplementary Table 1 
(Supplemental Digital Content, http://links.lww.com/JTO/
A687). Tissue tracking was also systematically recorded, allow-
ing verification of biological material availability.
Statistical Analysis
Comparison of patient and tumor characteristics was 
performed by Fisher’s exact and Mann-Whitney tests for 
categorical and continuous variables, respectively. Adjustment 
for multiple testing was not used. All tests performed were two-
sided. Statistical analysis was performed in SAS version 9.3.
Log-rank tests and Cox model Wald tests were used for 
comparisons of time-to-event end points between subgroups 
of interest. The outcome is measured by three time-to-event 
end points: OS, RFS, and TTR. OS is defined as time from 
surgery until death. RFS is defined as time from surgery until 
documented relapse or death from any cause. To avoid com-
peting risks of death and better define the surgical outcome, 
the end point of TTR is used. TTR is defined as the time from 
surgery until documented relapse or death due to the disease. 
The difference between RFS and TTR lies in the fact that all 
deaths—regardless of the cause of death—are counted as RFS 
events, whereas only deaths caused by the disease are counted 
as TTR events. For cases with documented relapse and miss-
ing relapse date, the date of relapse is substituted by the death 
date or the last follow-up date, if the patient is still alive. For 
all time-to-event end points, if the relevant event was not 
observed, the last day of follow-up is taken as the censoring 
date. Landmark analyses at different time points were used for 
exploring the association of OS with RFS and TTR.
Cox proportional hazards regression was used to model 
the association of the time-to-event end points with the charac-
teristics of interest and estimate hazard ratios (HRs) along with 
their corresponding 95% confidence intervals. In multivariate 
models, using the backward selection method, with removal 
criterion of 10%, the association with outcome of each factor 
in the presence of others in the model was explored. Observed 
differences in time-to-event end points were depicted via 
Kaplan–Meier curves. Median follow-up time was estimated 
using the reverse censoring method for OS.
Cumulative incidence plots were created to explore 
time-to-local and time-to-distant recurrence.5 Patients with 
missing site of relapse were excluded from this analysis, 
whereas patients with both types of recurrence were consid-
ered as having distant recurrence.
RESULTS
As of March 11, 2013, a total of 2449 retrospective 
cases of NSCLC have been captured in the Lungscape iBio-
bank (Supplementary Table 2, Supplemental Digital Content, 
http://links.lww.com/JTO/A687). For all patients, surgery was 
performed no later than 2009 (91.5% with surgery from 2003 
to 2009), and complete information was available on medical 
history, histology, and pathological TNM staging. Almost all 
patients with status alive at last follow-up have been followed 
for more than 3 years, with the exception of 43 patients with 
follow-up between 2 and 3 years.
Patient, Tumor, and Treatment Characteristics
The majority of patients are men (65.4%), with median 
age at surgery of 66 years (range, 23–90 years), and of white 
ethnicity (93.9%). Most are characterized as either current 
(31.9%) or former smokers (49.8%), whereas 13.8% are 
recorded as never smokers. Smoking history is unknown for 
only 4.5% of patients. Performance status (PS) at diagnosis 
is captured for 52.1% of the cohort, and the overwhelming 
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majority of these patients have a PS of 0 (61.2%) or 1 (35.6%). 
Previous history of cancer was reported in 14.1% of patients, 
whereas the majority of patients had no cancer previously 
(71.1%). Information is lacking for 14.7% of the cohort 
(Table 1). The majority of patients have adenocarcinoma 
(51.2%) and 40.7% squamous cell histology. The remaining 
Pathological stage, n (%)
  IA 560 (22.9)
  IB 644 (26.3)
  IIA 415 (16.9)
  IIB 292 (11.9)
  IIIA 499 (20.4)
  IIIB 39 (1.6)
Localization of primary tumor, n (%)
  Upper lobe R 757 (30.9)
  Upper lobe L 666 (27.2)
  Lower lobe L 383 (15.6)
  Lower lobe R 341 (13.9)
  Middle lobe R 127 (5.2)
  Overlapping over several lobes 110 (4.5)
  Central tumor 64 (2.6)
  Missing 1 (0.0)
Tumor size (cm)
  n (%) 2447 (99.9)
  Mean (95% CI) 4.0 (3.9–4.1)
  Median (min–max) 3.5 (0·2–16.0)
  ≤4 1564 (63.9)
  >4 883 (36.1)
Pleural invasion, n (%)
  No 1610 (65.7)
  Yes 814 (33.2)
  Missing 25 (1.0)
Type of surgery
  Anatomy, n (%)
   Lobectomy 1791 (73.1)
   Pneumonectomy 333 (13.6)
   Bilobectomy 157 (6.4)
   Wedge resection 88 (3.6)
   Segmentectomy 39 (1.6)
   Other 26 (1.1)
   Missing 15 (0.6)
  Technique, n (%)
   Open thoracotomy 2246 (91.7)
   Thoracoscopy 118 (4.8)
   Missing 85 (3.5)
Adjuvant treatment
  Chemotherapy, n (%)
   No 1531 (62.5)
   Yes 557 (22.7)
   Unknown/missing 361 (14.7)
  Radiotherapy, n (%)
   No 1953 (79.8)
   Yes 98 (4.0)
   Unknown/missing 398 (16.3)
CI, confidence interval; BMI, body mass index; R, right; L, left.
TABLE 1. (Continued)
Characteristics Total (n = 2449)
TABLE 1.  Patient, Tumor, and Treatment Characteristics 
(n = 2449)
Characteristics Total (n = 2449)
Sex, n (%)
  Male 1602 (65.4)
  Female 847 (34.6)
Age at surgery (yr)
  n (%) 2448 (99.9)
  Mean (95% CI) 65.0 (64.6–65.4)
  Median (min–max) 65.9 (22.6–89.5)
Ethnicity, n (%)
  White 2300 (93.9)
  Asian (East/South) 141 (5.8)
  South American 4 (0.2)
  African 3 (0.1)
  Missing 1 (0.0)
Smoking history, n (%)
  Current 782 (31.9)
  Former 1219 (49.8)
  Never 338 (13.8)
  Unknown 110 (4.5)
Performance status at diagnosis, n (%)
  0 781 (31.9)
  1 454 (18.5)
  2 32 (1.3)
  3 9 (0.4)
  Unknown 551 (22.5)
  Missing 622 (25·4)
Previous history of cancer, n (%)
  No 1742 (71.1)
  Yes 346 (14.1)
  Missing 361 (14.7)
BMI (kg/m2)
  n (%) 1186 (48.4)
  Mean (95% CI) 25.3 (25.1–25.6)
  Median (min–max) 24.9 (14.8–59.1)
Histology, n (%)
  Adenocarcinoma 1255 (51.2)
  Squamous cell 997 (40.7)
  Large cell 107 (4.4)
  Adenosquamous 54 (2.2)
  Combined/mixed (with or without parts of SCLC) 28 (1.1)
  Sarcomatoid 8 (0.3)
(Continued)
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8.1% of the cohort consists of large cell, adenosquamous, 
combined/mixed, and sarcomatoid subtypes. The stage dis-
tribution is as follows: IA 22.9%, IB 26.3%, IIA 16.9%, IIB 
11.9%, IIIA 20.4%, and IIIB 1.6%. The majority of tumors 
are reported as right upper lobe (30.9%), followed by left 
upper lobe (27.2%), left lower lobe (15.6%), and right lower 
lobe (13.9%). The median tumor size was 3.5 cm (range, 
0.2–16.0 cm). Most patients have undergone radical resection, 
including lobectomy in 73.1%, pneumonectomy in 13.6%, 
and bilobectomy in 6.4%. The majority of patients under-
went open thoracotomy (91.7%), whereas thoracoscopy was 
reported in only 4.8% of patients. Adjuvant chemotherapy was 
administered to 22.7% of patients, including 10.6%, 29.8%, 
and 40.7% of patients with stages I, II, and III, respectively. 
Only 4.0% received postoperative radiotherapy, including 
3.3% and 12.3% of patients with stages II and III, respectively.
Comparing the baseline characteristics between patients 
with adenocarcinoma and squamous cell carcinoma, previ-
ous history of cancer, body mass index, and adjuvant treat-
ment (chemotherapy/radiotherapy) do not differ significantly 
between the histology groups (Supplementary Table 3, 
Supplemental Digital Content, http://links.lww.com/JTO/
A687). Patients with adenocarcinoma histology are more 
often women (45.3% versus 20.7% for squamous), younger 
(median age 65.1 versus 67.1 years), never smokers (19.4% 
versus 6.8%), with PS of 0 (34.3% versus 28.2%), tumors of 
stage I (54.5% versus 44.7%), localization on the upper right 
lobe (35.4% versus 25.1%), and smaller tumor size (median 
3.0 versus 4.0 cm). Regarding the type of surgery, patients with 
adenocarcinoma have more often lobectomy (79.6% versus 
65.5%) and less often pneumonectomy (6.9% versus 22.0%) 
compared with patients with squamous cell carcinoma.
Outcome Overall and According 
to Pathological TNM Stage
The median time to follow-up of the whole cohort of 
patients is almost 5 years (59.4 months; interquartile range, 
47.5–76.5 months). At the last follow-up evaluation, almost 
half of the patients remain without evidence of disease (1151 
patients, 47.0%), whereas 143 patients (5.8%) are alive with 
disease. There are 1147 reported deaths, with 812 patients 
(33.2% of the total cohort) who died with evidence of recur-
rent disease and 306 patients (12.5%) who died without such 
evidence. The disease status is unknown in only 1.5% of 
patients (eight alive and 29 dead). The estimated median OS 
is 68.3 months, whereas OS at 5 years is 53.2%. The 5-year 
survival is 69.6% and 63.6% for stages IA and IB, 51.6% 
and 47.7% for stages IIA and IIB, and 29.0% and 13.0% for 
stages IIIA and IIIB, respectively (p < 0.001; Figure 1A). 
The observed RFS events are 1290 (52.7% of 2449 patients), 
whereas the median and the 5-year RFS are 52.8 months and 
47.3%, respectively. The 5-year RFS is 62.5% and 57.8% for 
stages IA and IB, 47.9% and 43.8% for stages IIA and IIB, 
and 21.0% and 13.2% for stages IIIA and IIIB, respectively (p 
< 0.001; Figure 1B).
A total of 955 patients experienced a TTR event (39.0%). 
The median TTR is 108 months, whereas the free of relapse 
estimate at 5 years is 58.1%. The respective estimates by stage 
level are 73.6% and 69.8% for stages IA and IB, 58.0% and 
53.4% for stages IIA and IIB, and 29.9% and 28.8% for stages 
IIIA and IIIB, respectively (p < 0.001; Figure 1C). Landmark 
analyses at 6, 12, 18, and 24 months indicated consistently 
that both RFS and TTR were strongly associated with OS (log-
rank p < 0.001 in all).
Of the 955 patients with a relapse, 833 (87.2%) have 
available information on the site of relapse. Distant relapse is 
recorded for 44.4%, local relapse for 26.0%, and both distant 
and local relapse for 16.9% of the 955 patients. Within 3 years 
of follow-up, 67.0% of the relapses occurred with 68.4% of 
documented distant or combined (local and distant) relapses 
and 58.5% of documented local relapses occurring by 3 years. 
Local and distant relapses are competing risks in the TTR 
definition. Exploration of time-to-local and time-to-distant 
relapse overall and by tumor stage is presented in Figure 2A 
and 2B. An increasing hazard by stage is observed for both 
local and distant relapses (p < 0.001 and p < 0.001, excluding 
patients with missing site of relapse).
Influence of Clinical and Tumor Characteristics
The potential influence of patient, tumor, and treatment 
characteristics on outcome is assessed by both univariate and 
multivariate analyses. The results of the univariate analysis are 
summarized in Supplementary Table 4 (Supplemental Digital 
Content, http://links.lww.com/JTO/A687). Smoking history is 
associated with OS (p = 0.048) but not RFS and TTR. Current 
or former smoking is adversely affecting OS compared with 
never smoking (HR = 1.23, p = 0.037 and HR = 1.25, p = 0.02, 
respectively). OS differs significantly by sex, with median OS 
for female patients being higher compared with male patients 
(77.7 versus 62.2 months; p = 0.0039). A significantly higher 
median RFS is also observed for women compared with men 
(62.9 versus 48.5 months; p = 0.008), whereas TTR does not 
differ by sex. No significant difference in OS, RFS, and TTR 
is observed between various histologies (p = 0.14), except for 
a marginally significant difference in OS between adenocarci-
noma and squamous cell histology (p = 0.049; Supplementary 
Figure 1A–C, Supplemental Digital Content, http://links.lww.
com/JTO/A687).
Based on the results of the multivariate analysis for all 
three time-to-event end points (Figure 3A–C), factors in the 
presence of other candidate prognostic variables that are sig-
nificantly associated with all three outcomes are PS (OS: 1 
versus 0: HR = 1.30, p = 0.0045; RFS: 1 versus 0: HR = 1.30, 
p = 0.0026; TTR: 1 versus 0: HR = 1.35, p = 0.0021), and tumor 
stage (OS: HRs increasing from 1.32 for IB versus IA to 3.89 
for IIIA and IIIB versus IA with all p values significant; HRs 
similar for RFS and TTR). Other variables significantly asso-
ciated with outcome, along with PS and stage, are the follow-
ing patient characteristics—for OS: sex (male versus female: 
HR = 1.14, p = 0.044), age (60–70 versus <60, HR = 1.28, 
p = 0.0014; >70 versus <60, HR = 1.45, p < 0.0001), and pre-
vious history of cancer (yes versus no: HR = 1.22, p = 0.021); 
for RFS: age (60–70 versus <60, HR = 1.24, p = 0.0027; >70 
versus <60, HR = 1.36, p < 0.001) and type of surgery—
anatomy (all others versus lobectomy: HR = 1.31, p = 0.012); 
and for TTR: histology (adenocarcinoma versus squamous: 
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A
B
FIGURE 1. A, Overall survival (OS) 
by pathological stage. B, Relapse-free 
survival (RFS) by pathological stage. 
C, Time to relapse (TTR) by patho-
logical stage.
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HR = 1.19, p = 0.014). Adjuvant chemotherapy did not have 
a differential effect on the survival of patients with or with-
out the high-risk features of tumor size above 4 cm or visceral 
pleural involvement (Supplementary Table 5, http://links.lww.
com/JTO/A687). For stage III, where 40% of patients received 
adjuvant chemotherapy, additional analyses showed a treat-
ment benefit for OS (chemotherapy versus no: HR = 0.787, 
p = 0.040), a finding that was not significant for stages I and II 
(interaction p = 0.020).
No other patient, tumor, or treatment characteristic is 
found to be significantly associated with any of the three time-
to-event outcomes in the presence of other variables. In addi-
tion, no significant interaction is detected between the variables.
DISCUSSION
The Lungscape project was launched by the European 
Thoracic Oncology Platform to study the molecular epidemi-
ology on NSCLC by collecting the largest series of clinically 
annotated surgical NSCLC cases. At the time of this analysis, 
2449 cases have been accepted in the database. This report is 
unique by providing outcome data beyond just stage and OS 
of a large cohort of surgically treated patients with NSCLC. It 
analyzes for the first time all three outcome parameters, OS, 
RFS, and TTR, determining the potential prognostic value of 
every clinicopathological characteristic in addition to the ana-
tomical staging based on the seventh TNM classification. The 
RFS and TTR analyses are important to describe for this cohort 
because they better reflect tumor biology and are less depen-
dent on age and other comorbidities than OS. This virtual 
annotated biobank also provides the basis for Lungscape’s next 
steps aiming at describing the molecular landscape of resected 
NSCLC looking at several distinct molecular biomarkers and 
their individual influence on NSCLC disease history.
Stage by stage, the 5-year survival reported matches the 
survival of pathological stage NSCLC from the International 
Association for the Study of Lung Cancer database, which 
formed the basis for the seventh TNM edition.2 The Lungscape 
data set is, therefore, a valid resource to examine the prognos-
tic influence of clinical as well as molecular parameters on the 
outcome of resected NSCLC.
Surgical radical resection was the major selection cri-
terion for inclusion into Lungscape. Regarding the surgical 
outcome, in the univariate analysis, older age was associated 
with worse survival for OS and RFS, and this held true in the 
multivariate analysis. Only 22.7% of patients in Lungscape 
received adjuvant chemotherapy. Although the potential 
impact of cisplatin-based adjuvant chemotherapy was first 
demonstrated in 1995, general acceptance in clinical practice 
occurred only gradually after publication of the International 
Adjuvant Lung Cancer Trial and further meta-analyses.1,6–8 
Adjuvant radiotherapy was recorded in 4.0% of patients. A 
beneficial effect of postoperative radiotherapy for patients 
with stage III (N2) NSCLC has been suggested by a retrospec-
tive analysis of the Adjuvant Navelbine International Trialist 
Association trial9 as well as the Surveillance, Epidemiology, 
and End Results database.10 In our cohort, 40% of the patients 
with stage III disease received adjuvant chemotherapy, which 
was found to benefit their OS, whereas 12.3% of the stage III 
patients received postoperative radiotherapy, without signifi-
cant improvement in their outcome (data not shown).
Relapse was documented in 995 patients, with 58.5% 
documented local relapses and 68.4% distant or combined 
C
FIGURE 1. (Continued)
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local and distant relapses occurring within the first 3 years 
after surgery. Pathological stage was associated with an 
increased risk of local as well as distant relapses. These pat-
terns of relapse could inform future guidelines on follow-up 
schedules and support published expert opinion–based rec-
ommendations on the close follow-up of surgically treated 
patients for up to 3 years.11 Due to the retrospective nature 
of this study, there was no uniform mode of follow-up. This 
might have minimal impact on RFS and TTR estimation. 
However, in the major academic center setting of this study, 
patients were seen at least every 6 months after surgery for 
the subsequent 3 years, including a radiological assessment. 
These data thus reflect the real life situation where evidence 
as to the optimal follow-up of patients after curative surgery is 
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FIGURE 2 , A, CumuLaTiVe iNCideNCe PLOT FOR Time-TO-LOCaL ReLaPSe aCCORdiNg TO PaThOLOgiCaL STage. 
Note: Pathological stage categories combined as “i,” “ii,” and “iii.” B, Cumulative incidence plot for time-to-distant and 
 combined relapse according to pathological stage. Note: Pathological stage categories combined as “i,” “ii,” and “iii.”
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still lacking. It is important to note that, in repeated landmark 
analyses, the association of OS with RFS as well as with TTR 
was consistently found significant, a finding worth further 
exploration with additional methodology. As of to date, there 
are no evidence-based recommendations for optimal follow-
up after surgery. At a time when advances in radiotherapy tech-
niques offer additional treatment options with curative intent, 
follow-up might become especially important in the detection 
of local relapse. By multivariate analysis, histology was found 
to be significantly associated with TTR with a worse outcome 
for adenocarcinoma compared with squamous cell carcinoma. 
A similar differential effect was seen in the control group 
of the Adjuvant Navelbine International Trialist Association 
trial with respect to survival12 and in several surgical series 
A
B
FIGURE 3. A, Forest plot for the multivariate overall survival Cox model. B, Forest plot for the multivariate relapse-free survival Cox 
model. C, Forest plot for the multivariate time-to-relapse Cox model. hR, hazard ratio; Ci, confidence interval; PS, performance status.
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demonstrating a worse survival13 and a higher likelihood of any 
relapse14 and/or distant relapse15 in adenocarcinoma histology. 
Lung Cancer Study Group trials in 1121 surgically treated 
patients showed superior postoperative outcome for patients 
with squamous cell carcinoma over nonsquamous histology 
in all pTN categories and for survival in all but stage III dis-
ease.16 Higher PS was significantly associated with a poorer 
outcome. Our data confirm the report on prognostic factors in 
addition to stage in the International Association for the Study 
of Lung Cancer database, where PS was identified as a very 
important additional factor.13 Smoking history was obtained 
for 95.5% of patients in our database. A significant difference 
when comparing never with current and former smokers was 
only detected by univariate analysis for OS. Although there is 
evidence that smoking had a negative influence on outcome 
of patients with advanced-stage disease,17 data on smoking 
impact in large surgical series are scarce. Wu et al 18 reported 
that never smokers had a significantly better cancer-specific 
survival rate of 5 years after surgery than smokers, although 
histological subtype and stage were not taken into account. 
A recent series from Liverpool identified smoking as a risk 
for resected adenocarcinoma but not for squamous cell carci-
noma,19 and similar findings have been reported from Korea.20 
Our multivariate analysis findings on OS are in line with most 
of the previous reports demonstrating that male patients have 
a worse outcome after surgery.21–24 A large population-based 
Taiwan cancer registry demonstrated that women with lung 
cancer had a better median and 5-year survival.25
Lungscape is the first large series reporting on lung can-
cer surgical outcome measured not only by OS but also by RFS 
and TTR and presenting multivariate analysis including most of 
the significant clinical and pathological prognostic parameters 
reported to date. As tissue from all patients has been preserved 
locally and is available for detailed molecular investigations, 
Lungscape provides an excellent basis to evaluate the influence 
of molecular parameters on the disease outcome after radical 
resection, in addition to providing an overview of the molecu-
lar landscape of stage I to III NSCLC. The first such project on 
ALK translocations has been completed and communicated.26 
Ongoing projects include MET, P13K, and PTEN, and multi-
plex mutation testing.
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